PT Pyridam Farma (PYFA) Fundamentals 2026 — Revenue Analysis | SniperIQ
PT Pyridam Farma (PYFA) is a ID-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of Rp2.34T, trading at Rp208.00 on the JKT. This SniperIQ fundamentals page covers PT Pyridam Farma's valuation, profitability (net margin -13.0%), revenue (Rp2.76T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Pyridam Farma's market cap?
PT Pyridam Farma (PYFA) has a market capitalization of approximately Rp2.34T, trading at Rp208.00 on the JKT. Market cap moves with the live share price.
What is PT Pyridam Farma's P/E ratio?
PT Pyridam Farma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Pyridam Farma?
PT Pyridam Farma runs a net profit margin of -13.0%, a gross margin of 17.8%, and an operating margin of -5.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Pyridam Farma generate?
PT Pyridam Farma reported revenue of Rp2.76T for fiscal year 2025, with net income of -Rp379.7B and earnings per share (EPS) of -33.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Pyridam Farma pay a dividend?
PT Pyridam Farma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Pyridam Farma financially healthy?
PT Pyridam Farma carries a debt-to-equity ratio of 7.03x and a current ratio of 0.86x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Pyridam Farma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Pyridam Farma (PYFA) the key facts are: market cap Rp2.34T, revenue Rp2.76T, 52-week range 158-700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Pyridam Farma's full fundamentals live
Get PT Pyridam Farma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.